Pharmaust Limited (AU:PAA) has released an update.
PharmAust Limited, a clinical-stage biotech firm, has formally requested Orphan Medicinal Product Designation (OMPD) from the European Medicines Agency (EMA) for their drug monepantel, aimed at treating amyotrophic lateral sclerosis (ALS). Securing OMPD could grant the company a decade of market exclusivity in the EU for this treatment. The decision by the EMA’s Committee for Orphan Medicinal Products is anticipated in December 2024, following a 90-day evaluation of the application.
For further insights into AU:PAA stock, check out TipRanks’ Stock Analysis page.
